RU2378370C2 - Штамм молочнокислой бактерии для лечения воспаления при воспалительном заболевании кишечника, компонент, эффективный для лечения язвы, способ лечения воспаления при воспалительном заболевании кишечника, продукт (варианты) и композиция (варианты) - Google Patents

Штамм молочнокислой бактерии для лечения воспаления при воспалительном заболевании кишечника, компонент, эффективный для лечения язвы, способ лечения воспаления при воспалительном заболевании кишечника, продукт (варианты) и композиция (варианты) Download PDF

Info

Publication number
RU2378370C2
RU2378370C2 RU2007142174/13A RU2007142174A RU2378370C2 RU 2378370 C2 RU2378370 C2 RU 2378370C2 RU 2007142174/13 A RU2007142174/13 A RU 2007142174/13A RU 2007142174 A RU2007142174 A RU 2007142174A RU 2378370 C2 RU2378370 C2 RU 2378370C2
Authority
RU
Russia
Prior art keywords
strain
cells
inflammation
treating
inflammatory
Prior art date
Application number
RU2007142174/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2007142174A (ru
Inventor
Эамонн КОННОЛЛИ (SE)
Эамонн КОННОЛЛИ
Original Assignee
Биогайа Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биогайа Аб filed Critical Биогайа Аб
Publication of RU2007142174A publication Critical patent/RU2007142174A/ru
Application granted granted Critical
Publication of RU2378370C2 publication Critical patent/RU2378370C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2007142174/13A 2005-04-15 2006-04-12 Штамм молочнокислой бактерии для лечения воспаления при воспалительном заболевании кишечника, компонент, эффективный для лечения язвы, способ лечения воспаления при воспалительном заболевании кишечника, продукт (варианты) и композиция (варианты) RU2378370C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/107,438 2005-04-15
US11/107,438 US7344867B2 (en) 2005-04-15 2005-04-15 Selection and use of lactic acid bacteria for reducing inflammation in mammals

Publications (2)

Publication Number Publication Date
RU2007142174A RU2007142174A (ru) 2009-05-20
RU2378370C2 true RU2378370C2 (ru) 2010-01-10

Family

ID=37087291

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007142174/13A RU2378370C2 (ru) 2005-04-15 2006-04-12 Штамм молочнокислой бактерии для лечения воспаления при воспалительном заболевании кишечника, компонент, эффективный для лечения язвы, способ лечения воспаления при воспалительном заболевании кишечника, продукт (варианты) и композиция (варианты)

Country Status (16)

Country Link
US (2) US7344867B2 (enExample)
EP (1) EP1868622B1 (enExample)
JP (1) JP4740999B2 (enExample)
KR (1) KR101042123B1 (enExample)
CN (1) CN101160134B (enExample)
AU (1) AU2006234793B2 (enExample)
DK (1) DK1868622T3 (enExample)
ES (1) ES2606765T3 (enExample)
HU (1) HUE032297T2 (enExample)
LT (1) LT1868622T (enExample)
MX (1) MX2007012656A (enExample)
PL (1) PL1868622T3 (enExample)
PT (1) PT1868622T (enExample)
RU (1) RU2378370C2 (enExample)
SI (1) SI1868622T1 (enExample)
WO (1) WO2006110088A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2578577C2 (ru) * 2010-09-21 2016-03-27 Биогайа Аб Продукт, содержащий молочнокислые бактерии, и влагопоглотитель
US11324786B2 (en) 2017-11-20 2022-05-10 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria and use thereof
RU2778773C2 (ru) * 2017-11-20 2022-08-24 Юниверсити-Индастри Кооперэйшн Груп Оф Кён Хи Юниверсити Новые молочнокислые бактерии и их применение

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
US20110293710A1 (en) * 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
ES2402014B1 (es) 2011-09-07 2014-02-27 Consejo Superior De Investigaciones Científicas (Csic) Peptido secretado por lactobacillus plantarum con función inmunomoduladora
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
HUE042643T2 (hu) 2012-06-04 2019-07-29 Biogaia Ab Lactobacillus reuteri ATCC PTA 6475 csontveszteség
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
ES2874479T3 (es) * 2014-01-23 2021-11-05 Biogaia Ab Agentes que modulan el dolor gastrointestinal
JP2018510631A (ja) * 2015-03-26 2018-04-19 バイオガイア・エイビーＢｉｏｇａｉａ ＡＢ ヒスタミン産生細菌株及びがんにおけるそれらの使用
US10376563B1 (en) 2016-02-12 2019-08-13 Wisconsin Alumni Research Foundation Methods for systemically delivering polypeptides and microorganisms therefor
HUE062788T2 (hu) 2016-04-15 2023-12-28 Baylor College Medicine Lactobacillus reuteri MM4-1A alkalmazása az autizmus spektrumzavar kezelésében vagy megelõzésében
CN110893195B (zh) * 2019-09-30 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22
EP3897836B1 (en) 2019-11-08 2023-08-16 Biogaia AB Serotonin producing bacteria
CN114196581B (zh) * 2020-12-16 2023-06-13 江南大学 缓解高尿酸血症的罗伊氏乳杆菌ccfm1132及应用
WO2023007468A1 (en) 2021-07-30 2023-02-02 Helaina, Inc. Methods and compositions for protein synthesis and secretion
JPWO2023063314A1 (enExample) 2021-10-11 2023-04-20
KR102752058B1 (ko) * 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2161494C2 (ru) * 1995-06-07 2001-01-10 Биогайа Биолоджикс АБ Способ улучшения здоровья животных
WO2004031368A1 (en) * 2002-10-07 2004-04-15 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) * 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) * 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5837238A (en) * 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
AU5773600A (en) * 1999-06-30 2001-01-31 Board Of Regents Of The University Of Nebraska, The Method of isolation of regulated virulence determinants from bacterial pathogens
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2161494C2 (ru) * 1995-06-07 2001-01-10 Биогайа Биолоджикс АБ Способ улучшения здоровья животных
WO2004031368A1 (en) * 2002-10-07 2004-04-15 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MENARD S. et al. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport, Gut., 2004, v.53, n.6, p.821-828. MARCEAU M. et al. Yersinia pseudotuberculosis anti-inflammatory components reduce trinitrobenzene sulfonic acid-induced colitis in the mouse, Infect Immun., 2004, v.72, n.4, p.2438-2441. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2578577C2 (ru) * 2010-09-21 2016-03-27 Биогайа Аб Продукт, содержащий молочнокислые бактерии, и влагопоглотитель
US11324786B2 (en) 2017-11-20 2022-05-10 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria and use thereof
RU2778773C2 (ru) * 2017-11-20 2022-08-24 Юниверсити-Индастри Кооперэйшн Груп Оф Кён Хи Юниверсити Новые молочнокислые бактерии и их применение
US11963988B2 (en) 2017-11-20 2024-04-23 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria and use thereof

Also Published As

Publication number Publication date
RU2007142174A (ru) 2009-05-20
KR101042123B1 (ko) 2011-06-16
US7344867B2 (en) 2008-03-18
HK1115730A1 (en) 2008-12-05
KR20070121700A (ko) 2007-12-27
WO2006110088A1 (en) 2006-10-19
EP1868622A4 (en) 2011-11-02
ES2606765T3 (es) 2017-03-27
LT1868622T (lt) 2017-01-10
US20060233775A1 (en) 2006-10-19
DK1868622T3 (en) 2017-01-16
CN101160134B (zh) 2012-08-22
EP1868622A1 (en) 2007-12-26
CN101160134A (zh) 2008-04-09
PL1868622T3 (pl) 2017-04-28
US20080107635A1 (en) 2008-05-08
JP4740999B2 (ja) 2011-08-03
SI1868622T1 (sl) 2017-01-31
PT1868622T (pt) 2016-12-29
AU2006234793A1 (en) 2006-10-19
JP2008538288A (ja) 2008-10-23
EP1868622B1 (en) 2016-09-28
MX2007012656A (es) 2007-12-13
HUE032297T2 (en) 2017-09-28
AU2006234793B2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
US20080107635A1 (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
CN101171019B (zh) 免疫功能调节剂
Tejada-Simon et al. Ex vivo effects of lactobacilli, streptococci, and bifidobacteria ingestion on cytokine and nitric oxide production in a murine model
RU2246956C2 (ru) Штамм бактерий lactobacillus paracasei cncm i-2116 (ncc 2461), обладающий способностью предотвращать заражение эпителиальных клеток кишечника ротавирусами, вызывающими диарею, и средство для лечения и/или профилактики нарушений, ассоциируемых с диареей, вызываемой ротавирусами
SK280682B6 (sk) Bifidobaktérie a ich použitie
CN116024131B (zh) 一种植物乳杆菌菌株goldgut-lp101及用途
RU2262943C2 (ru) Сомногенная активность непатогенных молочно-кислых бактерий
WO2009068474A1 (en) Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
CN116790402A (zh) 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用
CN105132328A (zh) 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum strain suo及其用途
JP2617758B2 (ja) 抗体産生増強型免疫賦活剤
KR101277050B1 (ko) 조제유-수유 영아에서 전신 염증을 치료, 예방 또는감소하기 위한, 장쇄 다중불포화 지방산과 병용되는락토바실러스 람노수스 ｇｇ의 용도
CN101146544A (zh) 鼠李糖乳杆菌用于治疗、预防或减少配方喂养婴儿的全身性炎症的用途
CN105154362A (zh) 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum suo及其保健用途
RU2505304C2 (ru) Способ получения аутопробиотика, содержащего живые бифидобактерии и лактобациллы
RU2176668C1 (ru) ШТАММ БАКТЕРИЙ LACTOBACILLUS ACIDOPHILUS N.V.EP 317/402 "НАРИНЭ" ТНСи, ИСПОЛЬЗУЕМЫЙ ПРИ ПРИГОТОВЛЕНИИ ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКИХ ПРЕПАРАТОВ ДЛЯ НОРМАЛИЗАЦИИ КИШЕЧНОЙ МИКРОФЛОРЫ
HK1115730B (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
McCoy Effects of feeding Lactobacillus reuteri X-18 on blood chemistry and immune parameters in beagle (Canis familiaris) puppies
US20010043933A1 (en) Methods and compositions for modulating the immune systems of animals
Link et al. The effect of Bacillus licheniformis on haematological parameters in calves
HK1115067B (en) Immune function modulating agent
CN105132329A (zh) 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum Lee及其保健用途